Skip to main content
Equibles
ACAD logo

ACAD · Acadia Pharmaceuticals Inc · Metrics

Track ACAD — free

Use ACAD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACAD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.20 +0.01 (+0.02%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.51B
Shares
172.31M
Volume · Oct 22 257.45K Avg daily vol (3M) 1.86M

ACAD metrics

99 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$20.19
Market cap
$3.51B

Price action

20 metrics
Price change (1W)
+4.9%
Price change (30D)
-23.6%
Price change (3M)
-19.1%
Price change (6M)
-9.2%
Price change (YTD)
-24.4%
Price change (1Y)
-5.1%
Trailing year
Price change (5Y)
+11.9%
52-week high
$30.57
52-week low
$18.62
Change from 52-week high
-34.0%
Change from 52-week low
+8.4%
Annualized volatility
38.9%
Annualized volatility (3M)
45.7%
Beta
0.8
RSI (14D)
38.8
Price vs SMA 50
-19.2%
Price vs SMA 200
-15.6%
Avg volume (3M)
1.86M
Relative volume
0.8
Average dollar volume
$46.29M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
172.31M

Valuation

12 metrics
P / E (TTM)
9.1
Trailing earnings · reciprocal yield 11.0%
PEG ratio
0.7
EV / revenue
2.7×
reciprocal yield 36.5%
EV / EBITDA
—
EV / EBIT
36.2×
reciprocal yield 2.8%
P / sales
3.1×
reciprocal yield 32.5%
P / book
2.7
reciprocal yield 37.2%
FCF yield
4.2%
TTM · current market cap
Buyback yield
—
P / FCF
24.1
reciprocal yield 4.2%
P / operating cash flow
21.9
reciprocal yield 4.6%
Earnings yield
10.8%

Historical valuation

8 metrics
P / E historical average (3Y)
13.2×
reciprocal yield 7.5%
P / E historical average (5Y)
13.2×
reciprocal yield 7.5%
EV / revenue historical average (3Y)
3.7×
reciprocal yield 27.1%
EV / revenue historical average (5Y)
4.8×
reciprocal yield 20.8%
EV / EBIT historical average (3Y)
35.2×
reciprocal yield 2.8%
EV / EBIT historical average (5Y)
35.2×
reciprocal yield 2.8%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-24

Profitability

9 metrics
Gross margin
—
Operating margin
7.6%
Trailing 12 months
Net margin
33.4%
Gross profit (TTM)
$684.80M
Operating profit (TTM)
$86.37M
Net income (TTM)
$380.48M
Trailing 12 months
Diluted EPS (TTM)
$2.23
FCF margin
12.8%
Effective tax rate
-213.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$6.61
Gross profit per diluted share (TTM)
$4.18
Operating profit per diluted share (TTM)
$0.50
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$2.21
Operating cash flow per diluted share (TTM)
$0.93
Free cash flow per diluted share (TTM)
$0.85
Capital expenditures per diluted share (TTM)
$0.09
R&D per diluted share (TTM)
$1.92
Stock compensation per diluted share (TTM)
$0.34
Book value per share
$7.21

Growth

11 metrics
Revenue growth YoY
+16.4%
Year over year
Net income growth YoY
+18.1%
Revenue (TTM)
$1.14B
Trailing 12 months
EPS growth YoY
+12.5%
Shares change YoY
+2.5%
Year over year · more shares
Revenue CAGR (3Y)
+27.5%
Revenue CAGR (5Y)
+19.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
29.1%
Return on assets
21.8%
Debt / equity
0.0
Current ratio
3.4
EBITDA (TTM)
—
Free cash flow (TTM)
$145.62M
Quick ratio
3.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$384.99M
Latest balance sheet
Cash & equivalents
$384.99M
Total assets
$1.74B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$160.32M
Capital expenditures (TTM)
$14.69M
R&D (TTM)
$331.01M
SG&A (TTM)
$620.29M
Stock compensation (TTM)
$58.05M
R&D / revenue
29.1%
Stock compensation / revenue
5.1%

Ownership (13F)

9 metrics
13F filers
355
13F filer change QoQ
+8
Institutional ownership
98.2%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
51.7%
Private-fund adviser ownership
50.1%
Active holders' share change QoQ
-0.5%
Holder tenure
16.9
Price vs estimated holder cost
+16.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.2%

Short interest

3 metrics
Short interest
4.8%
Latest settlement · 2.9 days to cover
Days to cover
2.9d
Short-squeeze score
50 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.02M
Insider-sentiment score
44 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1070494 CUSIP 004225108 13F (30d) 42 filings 41 filers Visit website Investor relations